Pretty clear that the Smith & Nephew deal was simply for big pharma to get control of a potential competitor product to keep it from commercialisation. Management were naive. DW said they might challenge the behaviour in court at a later date if funds become available, but obviously it's not a priority at this stage.
Another Opportunity for PolyNovo: Bone Scaffolds, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.32 |
Change
-0.020(0.85%) |
Mkt cap ! $1.602B | |||
| Open | High | Low | Value | Volume |
| $2.35 | $2.37 | $2.30 | $2.354M | 1.012M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 11423 | $2.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.33 | 8018 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |